Cargando…
Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension
PURPOSE: We evaluate the safety and intraocular pressure (IOP)-lowering effect of 15-µg bimatoprost implant (higher dose than the currently approved product) compared with selective laser trabeculoplasty (SLT) in patients with open-angle glaucoma or ocular hypertension. METHODS: Randomized, phase 3,...
Autores principales: | Christie, William C, Basha, Mahdi M, Ho, Quoc, Kim, Kimmie, Craven, E Randy, Kolko, Miriam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578166/ https://www.ncbi.nlm.nih.gov/pubmed/37850049 http://dx.doi.org/10.2147/OPTH.S427976 |
Ejemplares similares
-
Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Medeiros, Felipe A., et al.
Publicado: (2022) -
Dose–Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure
por: Lee, Susan S., et al.
Publicado: (2019) -
24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
por: Craven, E. Randy, et al.
Publicado: (2019) -
Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series
por: de Moraes, Carlos Gustavo Vasconcelos, et al.
Publicado: (2009) -
Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
por: Seal, Jennifer R., et al.
Publicado: (2019)